Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging

Status Terminated

Clinical Trial Summary

The principal aim of this study is to investigate the cardiac uptake of 89Zr-GSK2398852 in subjects with transthyretin cardiomyopathy amyloidosis (ATTR-CM), and its biodistribution to other organs. Low doses of GSK2398852 will be co-administered at levels not high enough for therapeutic benefit. This study will be conducted in two parts: Part A and Part B. Subjects in Part A will participate in up to two dosing sessions and subjects in Part B will participate in one dosing session. Subjects will undergo up to 3 PET scans at varying intervals after 89Zr-GSK2398852 administration. The total duration of study will be approximately 3 to 4 months for subjects in Part A and approximately 2 months for subjects in Part B. Part B of the study will be triggered based on data obtained in Part A and other emerging data.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Amyloidosis

Clinical Trial Details

NCT number	NCT03417830
Study type	Interventional
Source	GlaxoSmithKline
Contact
Status	Terminated
Phase	Phase 1
Start date	April 6, 2018
Completion date	July 20, 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04893889` - Substudy (NCT04456582): Noninvasive Assessment of Myocardial Stiffness by 2D-SWE Ultrasound Technique (Two-dimensional Shear Wave Elastography) in Patients With Amyloidosis and Fabry Disease.	N/A
Withdrawn	`NCT04943302` - Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis	Phase 2
Active, not recruiting	`NCT02909036` - Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.	Phase 1
Completed	`NCT02816476` - Daratumumab Therapy for Patients With Refractory or Relapsed AL Amyloidosis	Phase 2
Completed	`NCT01083316` - Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis	Phase 2
Completed	`NCT01527032` - Risk-adapted Therapy for Primary Systemic (AL) Amyloidosis	Phase 2
Completed	`NCT02545907` - A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis	Phase 1/Phase 2
Recruiting	`NCT05263817` - A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis	Early Phase 1
Active, not recruiting	`NCT03201965` - A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis	Phase 3
Withdrawn	`NCT02589860` - Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant
Recruiting	`NCT05635266` - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Completed	`NCT02574676` - Quality of Life (QOL) Registry for Patients With AL Amyloidosis
Active, not recruiting	`NCT02260466` - Prevalence and Post-surgical Outcomes of CARdiac Wild-type TransthyrEtin amyloidoSIs in Elderly Patients With Aortic steNosis Referred for Valvular Replacement.	N/A
Withdrawn	`NCT02462213` - Prospective Identification of Cardiac Amyloidosis by Cardiac Magnetic Resonance Imaging	N/A
Recruiting	`NCT05577819` - Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF	N/A
Completed	`NCT01406314` - SAP Depleter Dose Assessment Study in Patients	Phase 1
Not yet recruiting	`NCT04985734` - Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) in Patients With Idiopathic Peripheral Neuropathy	N/A
Active, not recruiting	`NCT03584022` - Clinical Trial to Assess the Safety of a Novel Scaffold Biomaterial	N/A
Active, not recruiting	`NCT05235269` - A Study to Evaluate Organ Level Uptake Repeatability of 124I AT-01 in Subjects With Systemic Amyloidosis	Phase 2
Active, not recruiting	`NCT05199337` - Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis	Phase 1/Phase 2